By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ocular Therapeutix, Inc. 

204 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-895-3235 Fax: 781-895-3236


SEARCH JOBS


Industry
Biotechnology






Company News
Ocular Therapeutix (OCUL) Completes End-Of-Phase 2 Review With FDA For OTX-TP (Sustained Release Travoprost) For Glaucoma And Ocular Hypertension 4/28/2016 10:35:00 AM
Ocular Therapeutix (OCUL) To Host Investor Day On April 6, 2016 3/29/2016 10:20:51 AM
Ocular Therapeutix (OCUL) Reports Fourth Quarter And Full Year 2015 Financial Results 3/10/2016 10:41:46 AM
Ocular Therapeutix (OCUL) To Report Fourth Quarter And Full Year 2015 Financial Results 3/3/2016 11:09:52 AM
Ocular Therapeutix (OCUL) To Present At Two Upcoming Investor Conferences 2/18/2016 10:51:07 AM
Ocular Therapeutix (OCUL) Announces Phase 3 Clinical Development Plan For OTX-TP, An Innovative Therapy For Glaucoma And Ocular Hypertension 2/17/2016 11:38:30 AM
Ocular Therapeutix (OCUL) Strengthens Executive Management Team With The Appointment Of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., As Chief Medical Officer 1/11/2016 12:44:08 PM
Ocular Therapeutix (OCUL) Announces Encouraging Top-Line Results From Exploratory Phase 2 Trial For DEXTENZA In Patients With Inflammatory Dry Eye Disease 12/14/2015 1:15:12 PM
Ocular Therapeutix (OCUL) Announces FDA Acceptance Of NDA Filing For DEXTENZA For The Treatment Of Post-Surgical Ocular Pain 12/9/2015 8:45:29 AM
Ocular Therapeutix (OCUL) To Present At The Piper Jaffray 27th Annual Healthcare Conference 11/25/2015 7:39:09 AM
12345678
//-->